Publication | Open Access
<i>ARID1A</i> alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
182
Citations
23
References
2020
Year
Our findings suggest that <i>ARID1A</i> alterations merit further exploration as a novel biomarker correlating with better outcomes after checkpoint blockade immunotherapy.
| Year | Citations | |
|---|---|---|
Page 1
Page 1